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Abstract 22 
Purpose.2-CL-IB-MECA, (A3 adenosine receptor agonist)(A3AR) mediated cardioprotection is well 23 
documented although the intracellular signalling pathways associated remain unclear. Here we demonstrate a 24 
role of the pro-survival signalling pathways MEK1/2-ERK1/2 and PI3K/AKT and their effect on modifying 25 
Caspase-3 activityin A3AR mediated cardioprotection. 26 
Methods. Isolated perfused rat hearts or primary adult rat cardiac myocytes were subjected to ischaemia/hypoxia 27 
and reperfusion/reoxygenation, respectively. 2-CL-IB-MECA (1nM) was administered at the onset of 28 
reperfusion/reoxygenation in the presence and absence of either the PI3K inhibitor Wortmannin (5nM) or 29 
MEK1/2 inhibitor UO126 (10μM). Heart tissues were harvested for assessment ofp-ERK1/2(Thr202/Tyr204) or p-30 
AKT(ser473) status or underwent infarct size assessment.  Cardiac myocytes underwent flow-cytometric analysis 31 
for apoptosis, necrosis, cleaved-caspase 3 / p-BAD (ser112) activity post-reoxygenation.  32 
Results. 2-CL-IB-MECA significantly reduced infarct size compared to non-treated controls, where co-33 
administration with either of the kinase inhibitors abolished the infarct sparing effects. Administration of 2-CL-34 
IB-MECA at reperfusion significantly upregulated the status of p-ERK1/2 and p-AKT compared to time 35 
matched controls in a UO126 and Wortmannin sensitive manner respectively. 2-CL-IB-MECA when 36 
administered throughout reoxygenation significantly reduced apoptosis, necrosis, cleaved-caspase 3 activity and 37 
increased p-BAD (ser112) and p-BAD (ser136) activity in myocytes subjected to hypoxia/reoxygenation injury. 38 
The cytoprotective effect was abolished by co-administration with the kinase inhibitors Wortmannin and/or 39 
UO126.  40 
Conclusions. We have described the molecular mechanisms associated with A3AR mediated cardioprotection 41 
indicating a role for the pro-survival signalling pathways that decrease caspase-3 activity. These observations 42 
provide novel insight into the pharmacological effects of A3ARs in ameliorating myocardial 43 
ischaemia/reperfusion injury. 44 
 45 
Keywords: A3 Adenosine receptor, Reperfusion injury, MEK1/2, PI3K, Apoptosis, Caspase 3, BAD. 46 
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Introduction 50 
Adenosine is a purine nucleoside that is highlyabundantthroughout body where it plays a critical role in cellular 51 
function. Previous studies have shown adenosine, a metabolite of adenosine triphosphate (ATP), to accumulate 52 
within the interstitial fluid within the ischaemic myocardium(1). Increased adenosine has profound effects in the 53 
cardiovascular system including vasodilation,hypotension and bradycardia. Adenosine exerts its physiological 54 
responses via four purinergic G-protein coupled adenosine receptors designated A1, A2a, A2b and A3(2). 55 
Research over the past decade has implicated the putative role of adenosine in mediating an innate role in 56 
protecting the myocardium from the deleterious consequences of ischaemia-reperfusion (I/R) injury (3-6).A1, 57 
A2a, A2b and A3 have been shown to exhibit cardioprotective properties, although controversy remains regarding 58 
the precise timing of activation of these receptors required to induce cardioprotection, as well as their 59 
involvement in ischaemic preconditioning and postconditioning(7-11).The ability of adenosine and adenosine 60 
analogues to mediate cardioprotection is of clinical relevance as a possible adjunctive therapy to treat patients 61 
with myocardial infarction or during cardiac surgery to limit the consequences of reperfusion injury(12). 62 
Maddock et al. have previously shown activation of A3AR at the onset of reperfusion to protect the myocardium 63 
from post ischaemic injury via an anti-apoptotic/necrotic mechanism that was abolished in the presence of A3AR 64 
antagonist MRS 1191(8).A3 adenosine receptor-mediatedcardioprotection has also been reported to limit 65 
myocardial I/R injury in a number of animal models including therat (10), rabbit(13), guinea pig (14), mice (7, 66 
15)and dog (16).Adenosine receptors have previously been shown to be functionally expressed in a number of 67 
organs including the myocardium (17, 18).The protection afforded by A3AR agonists can be directly attributed to 68 
A3ARs, as in A3AR gene knock-out mice subjected to myocardial ischaemia reperfusion injury, administration 69 
of the A3AR agonist failed to induce cardioprotection(10). 70 
A3AR agonists have been reported to mediate protection from I/R injury in a number of organs including the 71 
feline lung (19-21) and rat brain(22, 23). A3AR agonists have also been shown to promote cell survival in HL-60 72 
leukaemia and U-937 lymphoma cells exposed to UV light by means of restricting apoptosis(24). Surprisingly, 73 
there is limited data available that indicates the mechanisms responsible for this protection in the intact heart, 74 
despite some information obtained in cellular models.  75 
Recent studies have shown that mitogen activated protein kinases MEK1/2 - extracellular regulated kinase 76 
(ERK1/2) and phosphatidylinositol 3 kinase (PI3K) to become activated by a range of stimuli like growth factors 77 
and hormones following receptor stimulation (25-28). Mitogen activated protein kinases (MAPKs) play a role in 78 
cell survival, growth and differentiation and apoptosis (29). In this context, the MEK1/2-ERK1/2-BADand 79 
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PI3K-AKTcell survival pathwayshave been shown in numerous studies to regulate cardioprotection upon 80 
receptor stimulation where it is referred to as the reperfusion injury salvage kinase pathway (RISK) (30).  81 
Studies by Germackand Dickenson showed direct stimulation of A3ARs in neonatal rat cardiomyocytes to be 82 
directly linked to the serine/threonine kinase ERK1/2 and AKT in a dose and time dependent manner in 83 
normoxic conditions (31, 32). These further showed that preconditioning with the A3AR agonist 2-CL-IB-84 
MECA protected neonatal myocytes from hypoxia/reoxygenation injury in neonatalmyocytes. Interestingly, a 85 
number of cardioprotective agents including insulin, bradykinin and erythropoietin have been shown to have 86 
infarct sparing effectswhen administered alone either before or during reperfusion via upregulation at AKT and 87 
ERK pro-survival kinases(30).  88 
The aim of this study was to evaluate the putative role of PI3K and MEK1/2 signalling pathways in A3AR 89 
receptor mediated cardioprotection, asprevious studies have shown A3ARs to activate PI3K and MEK1/2 in 90 
normoxic conditions. Therefore, it was feasible that the cardioprotection exerted by 2-Cl-IB-MECA when 91 
administered at reperfusion may involve potential recruitment of the PI3K and MEK1/2 MAPK signalling 92 
pathways.  93 
Infarct sizes were measured after 2-Cl-IB-MECA (1nM) was administered andthe mechanisms responsible for 2-94 
CL-IB-MECAdependent cardioprotection in the isolated perfused heart were assessed using the MEK1/2 95 
inhibitor UO126(10μM)and the PI3K inhibitor Wortmannin (5nM).Tissues were also harvested at various time 96 
points post reperfusion do determine the phosphorylation status of AKT(Ser473), ERK(Thr202/Tyr204) and BAD(Ser112). 97 
Furthermore, we investigated the effect of the A3AR agonist 2-CL-IB-MECA in the presence and absence of 98 
U0126 (10μM) or Wortmannin(5nM)when administered at reoxygenation on apoptosis, necrosis and cleaved-99 
caspase 3 activity in adult rat cardiomyocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation.  100 
 101 
Materials and Methods 102 
Chemicals:A3ARagonist 1-[2-Chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-b-D-103 
ribofuranuronamide (2-CL-IB-MECA), 1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene 104 
(UO126), (1S,6bR,9aS,11R,11bR) 11-(Acetyloxy)-1,6b,7,8,9a,10,11,11b-octahydro-1-(methoxymethyl)-9a,11b-105 
dimethyl-3H-furo[4,3,2-de]indeno[4,5,-h]-2-h]-2-benzopyran-3,6,9-trione (Wortmannin) were purchased from 106 
Tocris Cookson (Bristol.UK). Total ERK,AKT,p-ERK1/2 (Thr202 /Tyr204)p-AKT (Ser473), Cleaved-Caspase-3 107 
(Asp175) (5A1), p-BAD(Ser112) and p-BAD (Ser136) Rabbit mAb antibodies were purchased from New England 108 
Biolabs (Hertfordshire, UK). Alexa Fluor   488   F(ab’)2   fragment   of   goat   anti-rabbit IgG (H+L)was purchased 109 
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 5 
from Invitrogen (Paisley, UK). -actinantibody was purchased from Abcam (Cambridge, UK). Drugs were 110 
dissolved in DMSO and stored at -20C.  111 
Animals  112 
Male Sprague-Dawley rats were used in all experiments (350-400g b/w). Experiments were conducted in 113 
accordance with the Guidelines on the operation of Animals (Scientific Procedures) Act 1986. Animals were 114 
obtained from Charles River (Margate, UK).  115 
Isolated perfused heart preparation.  116 
Animals were sacrificed by cerebral dislocation. Hearts were rapidly excised and placed into ice-cold Krebs 117 
Heinsleit buffer (KH). Hearts were quickly mounted onto the Langendorff system and retrogradely perfused with 118 
modified Krebs Henseleit (KH) bicarbonate buffer containing (in mmol) NaCl 118.5, NaHCO3 25, KCL 4.8, 119 
MgSO4 1.2, KH2PO4 1.2, CaCl2 1.7, and glucose 11.KH buffer was gassed using 95% O2 and 5% CO2 and 120 
maintained at 37C.  121 
The left atrium was trimmed away and a latex isovolumic balloon was carefully introduced into the left ventricle 122 
and inflated up to 5-10mmHg. Functional recording was via a physiological pressure transducer connected to a 123 
bridge amp and a Powerlab (AD Instruments Ltd. Chalgrove, UK). Left ventricular pressure (LVDP), heart rate 124 
(HR) and coronary flow (CF) were measured at regular intervals. To induce regional ischaemia a surgical needle 125 
was inserted under the left main coronary artery and the ends of the thread were passed through a tube to form a 126 
snare. Tightening of the snare induced regional ischaemia and releasing the threadinitiated reperfusion. At the 127 
end of reperfusion, the snare was tightened to re-occlude the coronary artery branch.  128 
A solution of 0.25% Evans blue in saline was then infused slowly via the aorta to delineate the non risk zone of 129 
the myocardium, which stained dark blue. The hearts were weighed and frozen at -20C. Frozen hearts were then 130 
sliced into 2mm thick transverse sections and incubated in triphenyl-tetrazolium chloride solution (1% in 131 
phosphate buffer) at 37C for 10-12minutes and fixed in 10% Formalin for at least 4 hours.  132 
In the risk zone the viable issue stained red and infarct tissue appeared pale. The risk zone and infarct areas were 133 
traced onto acetate sheets. Using computerised planimetry (Summasketch II, Summagraphics) the percentage of 134 
infarct tissue within the volume of the myocardium at risk was calculated (I/R%).  135 
Experimental Groups. 136 
Isolated hearts were split into two groups. Group 1 hearts underwent a protocol for infarct size assessment as 137 
shown in Fig 1a. Group 2 hearts underwent protocols for western blotting as summarised in Fig 1b. 138 
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 6 
Protocol 1: All hearts were allowed to stabilise for 20min prior to being subjected to 35min regional ischaemia 139 
followed by 120min reperfusion. Hearts were randomly assigned to the following groups 1min before 140 
reperfusion. a) hearts perfused with KH buffer alone with no drugs(control); b) hearts perfused with 2-CL-IB-141 
MECA (1nM) throughout the duration of reperfusion, previously shown to be cardioprotective by Maddock et al. 142 
c) hearts perfused with 2-CL-IB-MECA (1nM) in the presence and absence of UO126 (10M) (highly specific 143 
MEK1/2 inhibitor) or Wortmannin (5nM)(selective irreversible inhibitor of PI3K) throughout the reperfusion 144 
period. 145 
Protocol 2: Hearts were allowed to stabilise for 20min after which they were randomly assigned to one of the 146 
following groups a) perfused for 60min b) 35min ischaemia with 5,10, or 20min reperfusion in the presence and 147 
absence of  2-CL-IB-MECA (1nM) c) 35min ischaemia followed by 10min reperfusion with 2-CL-IB-MECA in 148 
the presence and absence of U0126 (10M) or Wortmannin (5nM)d) 35 min ischaemia followed administered at 149 
the onset 10 min reperfusion in the presence and absence of UO126 (10 M) or Wortmannin (5nM).  150 
Protein Extraction 151 
At the end of each experiment tissues were isolated from the risk zone and snap frozen in liquid nitrogen. 152 
Tissues from the ischaemic zone were homogenised in suspension buffer containing (in mM) 0.1 NaCl, 10 Tris, 153 
1 EDTA (pH8), 2 sodium pyrophosphate, 2 NaF, 2 -glycerophosphate, 0.1mg/ml 4-(2-Aminoethyl) 154 
benzenesulfonyl fluoride hydrochloride (AEBSF) and protease inhibitor cocktail mixture (Roche, UK) at 4C 155 
using the IKA-Ultra-Turrax homogeniser. Samples were then centrifuged for 5min at 11,000 rpm and stored at -156 
80C until further analysis. Samples were assayed for protein content using the bicinchoninic acid (BCA) protein 157 
assay reagent kit (Pierce,Northumberland,UK). 158 
Western blot analysis 159 
Protein samples were mixed with an equal volume of sample buffer containing 100mM Tris (pH6.8), 200mM 160 
DTT, 2%SDS, 0.2% Bromophenol blue, 20% glycerol and heated to 95C for 10min and stored at -20C. 161 
Samples were defrosted on ice and 60g of protein were separated by SDS-PAGE (12.5% acrylamide gel) using 162 
a Bio-Rad mini protean II system.  163 
Proteins were transferred to polyvinylidenedifluoride (PVDF) membrane using the Bio-Rad mini Trans blot 164 
system. After transfer the membranes were washed with Ambo Life Tris buffered saline (TBS) and blocked for 1 165 
hour using TBS, 5%w/v non fat milk, 0.1% Tween-20. Blots were incubated overnight at 4C with the primary 166 
antibody to phosphor-AKT(Ser473) phospho-ERK1 / ERK2 (Thr202/Tyr204)at a dilution of 1:1000 in TBS, 5%w/v 167 
bovine serum albumin fraction V, 0.1% Tween-20. Blots were washed and incubated with anti rabbit 168 
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 7 
IgGantibody conjugated to horseradishperoxidase at a concentration of 1:2000 at room temperature for 1 hour. 169 
Blots were further washed and were incubated for a few seconds in enhanced chemiluminescence substrates 170 
(AMBO Lumifast ECL Kit).  171 
Blots were exposed to Hyperfilm ECL (Amersham, Buckinghamshire, UK) and developed using Kodak 172 
developing/fixing solution (Sigma, Poole. UK). Equal loading was confirmed by developing the blots for either 173 
total AKT, ERK1/2, antibody.The transfer efficiency was assessed by Ponceau S Stainingprior to primary 174 
antibody application. Films were scanned and the band densitometry was assessed using the NIH Image J 175 
(v1.33) software. 176 
Rat cardiac myocytemodel 177 
Adult rat cardiomyocytes were isolated by conventional enzymatic dissociation. Briefly, Male Sprague Dawley 178 
rats (350-500g body weight) were sacrificed by cerebral dislocation. Hearts were quickly excised and mounted 179 
on a modified Langendorff apparatus. Hearts were perfused with modified Krebs Heinsleit bicarbonate buffer 180 
(NaCl 116mM, NaHCO3 25.0mM, KCl 5.4mM, MgSO4 .7.H2O 0.4mM, CaCl2 1.7mM, glucose 10mM, taurine 181 
20mM, pyruvate 5mM and Na2HPO4.12H2O 0.9mM). The buffer was oxygenated with 95% O2 and 5% CO2 182 
(BOC Gases) and heated to 37C (pH 7.4).  183 
Hearts were perfused for 5 minutes with Krebs buffer containing calcium followed by 5 minutes of perfusion 184 
with calcium free Krebs Heinsleit buffer. Upon perfusion with calcium free buffer the heart ceased to contract. 185 
The hearts underwent a final 5 minute perfusion cycle with modified Krebs Heinsleit digestion buffer containing 186 
BSA 0.5%, Worthingtons Type II Collagenase 0.075%, CaCl2 4.4M pH 7.4 with NaOH. During perfusion with 187 
collagenase the effluent was collected and reused.  188 
After perfusion with collagenase the heart was removed and the atria were cut away.The ventricles were teased 189 
apart and incubated with fresh digestion buffer for 10 minutes on an orbital shaker. The digestion buffer was 190 
aspirated and was passed through a nylon mesh into a sterile falcon tube and centrifuged at 400 rpm for 2 191 
minutes.  192 
The supernatant was removed using a sterile pipette and the pellet was redistributed in 25ml freshly prepared 193 
restoration buffer (NaCl 116mM, NaHCO3 25.0mM, KCl 5.4mM, MgSO4 .7.H2O 0.4mM, glucose 10mM, 194 
taurine 20mM, pyruvate 5mM Na2HPO4.12H2O 0.9mM, 1% BSA and 1% Pen-Strep).  The calcium 195 
concentration was gradually brought back to 1.25mM.Myocyte viability was assessed using trypan blue and 196 
were discarded if the viability was below 70% or myocytes were incubated in suspension bufferfor 24 hours 197 
before being used in experiments. 198 
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 8 
Experimental Protocol. 199 
Cardiac myocytes were centrifuged at 500rpm for 5 min and buffer was replaced with hypoxic buffer (12 mM 200 
KCL, 0.49mM MgCl2, 0.9 mM CaCl2, 4 mM HEPES, 10 mMdeoxyglucose and 20 mMlactate). Myocytes were 201 
incubated in a pre-heated (37C) hypoxic chamber for 6 hours where the O2 was replaced with 5% CO2 balanced 202 
in Argon (BOC Gases). After hypoxia, cells were removed from the chamber and centrifuged at 500 rpm for 5 203 
minutes. The supernatant was removed and replaced with restoration buffer.The A3 agonist 2-Cl-IB-MECA 204 
(1nM) and the MEK1/2 inhibitor UO126 (10M) or PI3K inhibitor Wortmannin (5nM) were placed into the 205 
appropriate wells in the 24 well plate. Cells were also kept for the normoxic group and unstained group. 206 
Cells were reoxygenated in the incubator for 18 hours before undergoing fluorescence-activated cell sorting 207 
(FACS) analysis for assessment of cellular apoptosis , necrosis, cleaved-caspase3 and p-BAD (Ser112) and p-208 
BAD (Ser136) activity.  209 
Assessment of apoptosis and necrosis by FACS Analysis 210 
The Vybrant Apoptosis Assay Kit #10 (Invitrogen, Paisley,UK) provides a three-colour fluorescence assay that 211 
distinguishes live, apoptotic, and late apoptotic cells from one another. Cells were incubated with fluorochromes 212 
according   to   the  manufacturer’s   instructions. Briefly, cells were pelleted by centrifugation and resuspended in 213 
Annexin V buffer. The appropriate volumes of fluorescent probes were added to the cells and incubated at 37°C 214 
for 15 minutes. The samples were analysed on the FL-2 and FL-4 channels on the BD FACS Calibur® Flow 215 
cytometer and setup to count 10,000 events. Quantitative assessment of live, apoptotic and necrotic cell 216 
populations was made using the Cell Quest software.  217 
Assessment of p-BAD (Ser112) and p-BAD (Ser136) and cleaved-caspase 3 activity by FACS Analysis 218 
To determine the activity of p-BAD (Ser112), p-BAD (Ser136) and cleaved-caspase 3 in adult rat myocytes at the 219 
end of reoxygenation cells were centrifuged at 1200rpm for 2min(33). The supernatant was aspirated and the 220 
pellet was resuspended in 250l phosphate buffered saline andfixed by the addition of 250l of 6% 221 
formaldehyde. The cells were incubated for 10min at 37C and placed on ice for 1 min.  222 
The eppendorffs were centrifuged at 1200 rpm for 2min after which the supernatant was aspirated and the cells 223 
were permeabilised by resuspending in ice-cold methanol (90%). Cells were kept on ice for 30min and 224 
centrifuged at 1200 rpm for 2min. The supernatant was removed and the cells were with incubation buffer (0.5% 225 
BSA in PBS stored @ 4C). The eppendorffs were centrifuged at 1200 rpm for 2min followed by the removal of 226 
the supernatant. The cells were blocked by the addition of 100l of incubation buffer for 10 minutes at room 227 
temperature. The cleaved-Caspase 3ASP175 (5A1) rabbit monoclonal primary antibody or p-BAD (ser112) (New 228 
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 9 
England Biolabs, Hitchin, UK) was added to the blocking buffer to give a final concentration of 1:100 and 229 
incubated at room temperature for 60 minutes.  230 
Theeppendorffs were centrifuged again at 1200 rpm for 2 minutes followed by the removal of supernatant and 231 
washed twice in incubation buffer.  The cells were resuspended in 200l of incubation buffer containing the 232 
Alexa Fluor® 488 secondary antibody (Invitrogen®) to give a final concentration of 1:1000. The samples were 233 
covered in foil and incubated for 30 minutes at room temperature. The cells were centrifuged at 1200 rpm for 2 234 
min and washed in incubation buffer. Finally, the cells were resuspended in 500l of phosphate buffered saline 235 
and analysed on the BD FACS Calibur® flow cytometer on the FL-1 channel. Histograms were plotted for each 236 
of the groups showing the mean fluorescence for 10,000 counts.  237 
Statistical Analysis 238 
All values are expressed as mean SEM. Infarct size, cell death and band densities were tested for group 239 
differences using one way analysis of variance (ANOVA) with Fishers post hoc tests. A P-value of P<0.05 was 240 
considered statistically significant. Left ventricular developed pressure, heart rate and coronary flow were 241 
assessed for statistical difference using a Two way ANOVA for repeated measures. 242 
Exclusion Criteria 243 
In total 5 hearts were excluded from the study where heart rate or left ventricular developed pressure failed to 244 
recover during the stabilisation phase.  245 
 246 
Results 247 
 Homogeneity among the experimental groups 248 
The results from 68successful experiments were included. Heart rate, coronary flow and left ventricular 249 
developed pressure were not significantly different during stabilisation, ischaemia and reperfusion in all groups 250 
(data not included). 251 
Protection afforded by the A3AR agonist 2-CL-IB-MECA when administered at reperfusion is mediated via 252 
MEK1/2 activity 253 
Isolated perfused rat hearts underwent 35 minutes of ischaemia followed by 120min of reperfusion where the A3 254 
agonist 2-CL-IB-MECA (1nM) was administered throughout the reperfusion period. Our studies showed that the 255 
administration of the highly specific A3AR agonist 2-Cl-IB-MECA (1nM) throughout the reperfusion period 256 
significantly attenuated infarct development (% of the risk area) (I/R %) from 65  1.7% in control hearts to 32 257 
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4% in 2-CL-IB-MECA treated hearts, a reduction of 51% (P<0.01, Fig.2). The cardioprotective effect of 2-CL-258 
IB-MECA has previously been demonstrated by Maddock et al..(8). 259 
To determine whether the protection afforded by the A3AR agonist 2-Cl-IB-MECA (1 nM) when administered at 260 
reperfusion was mediated via MEK1/2 activity, we used the MEK1/2 inhibitor UO126 (10 M). Alone, UO126 261 
had no significant effect on infarct size compared to control (55  8% vs. 65  1.5% control P>0.05, Fig.2).  262 
Co-administration of UO126 in the presence of 2-CL-IB-MECA significantly abrogated the protection afforded 263 
by 2-CL-IB-MECA (59  9% vs. 32  4% 2-CL-IB-MECA P<0.05, Fig.2). These data suggest that MEK1/2 264 
dependent signalling pathways are involved in A3AR mediated cardioprotection when administered at 265 
reperfusion. 266 
Protection afforded by the A3AR agonist 2-CL-IB-MECA at reperfusion is mediated via PI3K activity 267 
To determine whether the protection afforded by the A3AR agonist 2-Cl-IB-MECA (1 nM) when administered at 268 
reperfusion was mediated by enhanced PI3K activity, we used the PI3K inhibitor Wortmannin (5nM). Alone, 269 
Wortmannin had no significant effect on infarct size compared to control (65  8% vs. 65  2% respectively, 270 
P>0.05, Fig.3).  271 
Co-administration of Wortmannin with 2-CL-IB-MECA significantly abrogated the protection afforded by 2-272 
CL-IB-MECA (68  12% vs. 32  4% P<0.05; respectively, Fig.3). These data suggest that PI3K dependent 273 
signalling pathways are also involved in A3AR mediated cardioprotection when administered at reperfusion. 274 
The role of MEK1/2 – ERK1/2 MAPK pathway in A3 adenosine receptor mediated cardioprotection in adult 275 
rat cardiomyocytes subjected to hypoxia/ reoxygenation injury 276 
As shown in Figure 4 and 6, isolated adult rat cardiac myocytes underwent 6 hours of hypoxia followed by 18 277 
hours of reoxygenation resulting in a 3.2 fold increase in the number of apoptotic cells (41.8 ± 5.4% vs. 12.9 ± 278 
1.3% normoxic group, P<0.001), and a 3.1 fold increase in the number of necrotic cells (33.2 ± 2 vs. 10.7 ±2.1% 279 
normoxic group, P<0.001, Fig 4). 280 
To ascertain the role of A3ARs in limiting the deleterious consequences of reoxygenation injury the A3AR 281 
agonist 2-Cl-IB-MECA (1 nM) was administered throughout the reoxygenation period.  Administration of the A3 282 
agonist 2-Cl-IB-MECA (1 nM) significantly decreased the percentage of apoptotic myocytes (26 ± 6% vs. 41.8 ± 283 
5.4 % Hyp/Reox group, P<0.001, Fig 4), and necrotic myocytes (16 ± 4 vs. 33.2 ± 2 Hyp/Reox group, P<0.001, 284 
Fig 4).  285 
Administration of the A3 adenosine receptor agonist 2-Cl-IB-MECA (1 nM) at reoxygenation significantly 286 
decreased the number of apoptotic and necrotic myocytes compared to non-treated groups. To determine which 287 
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mechanisms are involved in 2-CL-IB-MECA mediated cardioprotection we assessed the role of the MEK1/2 – 288 
ERK1/2 cell survival pathway using the MEK1/2 inhibitor UO126 (10 M). Cardiac myocytes were incubated 289 
with the MEK1/2 inhibitor UO126 (10 M) in the presence and absence of the A3 agonist 2-CL-IB-MECA (1 290 
nM).   291 
Co-administration of the A3 agonist 2-CL-IB-MECA (1 nM) with the MEK 1/2 inhibitor UO126 (10 M) 292 
significantly abolished the anti-apoptotic (38 ± 4 % vs. 26 ± 6 % 2-CL-IB-MECA, P<0.001) and anti-necrotic 293 
potential of 2-Cl-IB-MECA (25 ± 3 vs. 16 ± 4 2-CL-IB-MECA, P<0.001, Fig 4 ). UO126 alone had no 294 
significant effect of cellular apoptosis when compared to the hypoxic reoxygenated group (42 ± 6 % vs. 42 ± 5 295 
% Hyp/Reox, P>0.05, Fig 4). UO126 when administered at reoxygenation was seen to significantly decrease the 296 
number of cells dying by cellular necrosis when compared the hypoxic reoxygenated group (23 ± 3 % vs. 32.2 % 297 
vs. Hyp/Reox, P<0.05,  Fig 4). 298 
The role of PI3K survival pathway in A3 adenosine receptor mediated cardioprotection in adult rat 299 
cardiomyocytes subjected to hypoxia/ reoxygenation injury. 300 
Administration of the A3 adenosine receptor agonist 2-Cl-IB-MECA (1 nM) at reoxygenation significantly 301 
decreased the number of apoptotic and necrotic myocytes compared to non-treated groups. To determine which 302 
cellular mechanisms are involved in 2-CL-IB-MECA mediated cytoprotection we assessed the role of the PI3K 303 
cell survival pathway using the PI3K inhibitor Wortmannin (5 nM).  304 
Administration of the A3 agonist 2-CL-IB-MECA (1 nM) in the presence of the PI3K inhibitor Wortmannin (5 305 
nM) significantly abolished the anti-apoptotic effect of 2-CL-IB-MECA (1 nM) compared to when administered 306 
alone throughout reoxygenation (37 ± 6 % 2-CL-IB-MECA + Wortmannin vs. 26 ± 6 % 2-CL-IB-MECA, 307 
P<0.05, Fig 5).  308 
Administration of 2-CL-IB-MECA (1 nM) in the presence of the PI3K inhibitor Wortmannin (5 nM) also 309 
significantly abolished the anti-necrotic effect of 2-CL-IB-MECA (1 nM) when administered alone throughout 310 
reoxygenation (28 ± 3 % 2-CL-IB-MECA + Wortmannin vs. 16 ± 4 % 2-CL-IB-MECA, P<0.05, Fig 5). 311 
Wortmannin (5 nM) alone had no significant effect of cellular apoptosis when compared to the Hyp/Reox group 312 
(36 ± 5% Wortmannin vs. 42 ± 5 % Hyp/Reox, P>0.05) Fig 5. Interestingly, Wortmannin (5 nM) when 313 
administered alone throughout reoxygenation was seen to have a significant effect on reducing cellular necrosis 314 
when compared to the Hyp/Reox group (22 ± 3% Wortmannin vs. 32 ± 2 % Hyp/Reox P<0.001, Fig 5. 315 
Time course of ERK 1/2 phosphorylation in non treated and 2-CL-IB-MECA ischaemic reperfused rat hearts  316 
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In order to investigate the role of MAPKs ERK1/2 inA3AR mediated cardioprotection 2-CL-IB-MECA (1 nM) 317 
was administered at reperfusion and the heart tissues were harvested at different time intervals in both treated 318 
and non-treated groups and assessed by western blot analysis for total and Phospho-ERK1/2. 319 
Administration of the A3 agonist 2-Cl-IB-MECA (1nM) at reperfusion significantly upregulated the 320 
phosphorylation of ERK1/2 after 10 minutes of reperfusion  (P<0.05; Fig 6) compared to non-treated time 321 
matched controls. This upregulation of ERK 1/2 phosphorylation by 2-CL-IB-MECA (1nM) after 10 minutes of 322 
reperfusion was abrogated by the co-administration of the MEK1/2 inhibitor UO126 (10M) (P<0.01; Fig 6).  323 
Administration of UO126 (10M) for 10 minutes of reperfusion had no significant effect of p-ERK expression 324 
compared to time matched controls (P>0.05; Fig 6).  Administration of Wortmannin alone or in the presence of 325 
2-CL-IB-MECA had no significant effect p-ERK levels. 326 
Time course of AKT (ser 473) phosphorylation in non-treated and 2-CL-IB-MECA treated ischaemic reperfused 327 
rat hearts.  328 
In order to determine the role of the PI3K/AKT pro-survival pathway in A3AR mediated cardioprotection we 329 
assessed the phosphorylation status of p-AKT (Ser 473), at various time intervals post reperfusion in the presence 330 
and absence of the A3 agonist 2-CL-IB-MECA (1 nM).  331 
Administration of 2-CL-IB-MECA (1nM) for 10 minutes of reperfusion significantly upregulated the 332 
phosphorylation of AKT (ser473) compared totime matched controls (P<0.01vs. time matched controls, Fig 7).2-333 
CL-IB-MECA dependent increase in p-AKT at 10 minutes of reperfusion was significantly reversed in the 334 
presence of the PI3K Inhibitor Wortmannin (P<0.001;Fig 7).Administration of Wortmannin (5nM) for 10 335 
minutes of reperfusion significantly decreased p-AKT expression compared to time matched controls (P<0.001; 336 
Fig 7). Administration of UO126 alone had no significant effect p-AKT compared to time matched control 337 
(P>0.05; Fig 7). Administration of UO126 + 2CL-IB-MECA significantly increased p-AKT compared to time 338 
matched control (P<0.01; Fig 7). 339 
Role of 2-CL-IB-MECA when administered at reoxygenation on p-BAD (ser112)and p-BAD (ser136) activity 340 
in isolated rat cardiomyocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation 341 
Recruitment of pro-survival pathways has been shown to inhibit by phosphorylation downstream pro-apoptotic 342 
protein such as BAD. BADis involved in initiating apoptosis, but when phosphorylated at Ser112  and Ser136 343 
BAD is inactivated and apoptosisisreduced. In order to investigate whether the cardioprotection observed by the 344 
administration of 2-CL-IB-MECA involved phosphorylation of p-BAD (Ser112) and p-BAD (Ser136),cardiac 345 
myocytes were subjected to hypoxia and reoxygenation injury where 2-CL-IB-MECA (1nM) was administered 346 
at reoxygenation in the presence and absence of the kinase inhibitors.  347 
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Administration of the A3 agonist 2-Cl-IB-MECA (1 nM) at reoxygenation significantly up regulated the 348 
phosphorylation of BADser112 and BAD ser136compared to the Hyp/Reox group (P<0.05) (Fig 8). Co-349 
administration of 2-CL-IB-MECA (1nM) with UO126 (10uM) or Wortmannin (5nM) significantly abolished 2-350 
CL-IB-MECA (1nM) mediated upregulation of p-BAD(ser112) and p-BAD (Ser136) respectively (P<0.05) (Fig 351 
8). The kinase inhibitors Wortmannin or UO126 alone had no significant effect on p-BAD(ser112) and p-BAD 352 
(Ser136)compared to the Hyp/Reox group (Fig 8). 353 
Role of 2-CL-IB-MECA when administered at reoxygenation on cleaved-caspase 3 activity in isolated rat 354 
cardiomyocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation 355 
Isolated adult rat cardiomyocytes subjected to 6 hours of hypoxia followed by 18 hours of reoxygenation 356 
resulted in a 2.5 fold increase in cleaved-caspase 3 activity compared to the normoxic group P<0.001 (Fig 9). 357 
Administration of the A3 agonist 2-Cl-IB-MECA (1nM) at reoxygenation significantly decreased Hyp/Reox 358 
dependent increases in cleaved-caspase 3 activity (P<0.001,Fig 9). The data strongly suggests that the 359 
cardioprotective effects of 2-CL-IB-MECA are via anti-apoptotic mechanisms. 360 
Role ofMEK1/2-ERK1 and PI3K 2 cell survival pathway in cleaved-caspase 3 activity upon administration of 361 
2-CL-IB-MECA (1nM) at reoxygenation in isolated myocytes subjected to hypoxia/reoxygenation injury. 362 
Administration of 2-Cl-IB-MECA (1nM) at reoxygenation significantly reduced cleaved-caspase 3 activity 363 
compared to non-treated isolated adult rat cardiomyocytes subjected to 6 hours of hypoxia and 18 hours of 364 
reoxygenation (P<0.001, Fig 9). To determine whether the decrease in cleaved - caspase 3 activity involved the 365 
MEK1/2 – ERK1/2 cell survival pathway we used the MEK1/2 inhibitor UO126 (10M) or PI3K inhibitor 366 
Wortmannin (5nM) in the presence and absence of 2-C-IB-MECA (1nM).  367 
Administration of the MEK1/2 inhibitor UO126 with the A3 agonist 2-CL-IB-MECA (1nM) at reoxygenation 368 
failed to block the decrease in cleaved-caspase 3 activityafforded when 2-CL-IB-MECA was administered alone 369 
at reoxygenation (P>0.05, Fig 9). UO126 when administered alone had no significant effect on cleaved-caspase 370 
3 activity compared to the Hyp/Reox group (P>0.05, Fig 9).  371 
Activation of A3ARs throughout reoxygenation significantly decreased cleaved-caspase 3 activitywhich was 372 
significantly abolished in the presence of the PI3K inhibitor Wortmannin (5 nM) (P<0.05,Fig 10). 373 
Administration of Wortmannin (5nM) throughout reoxygenation alone had no significant effect of cleaved-374 
caspase 3 activity compared to the non-treated Hyp/Reox(P>0.05,Fig 10).  375 
 376 
Discussion 377 
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The findings from the current study demonstrate that activation of adenosine A3 receptors at reperfusion protects 378 
the isolated perfused rat heart from ischaemia/reperfusion injury and cardiac myocytes from 379 
hypoxia/reoxygenation injury via recruitment of the survival kinases PI3K and MEK1/2. 380 
Our data are in agreement with those of Maddock and others whichhave previously shown that activation of 381 
A3AR at reperfusion significantly attenuated infarct development when administered during reperfusion(7, 8, 10, 382 
13, 14). The selective A3AR antagonist I-ABOPX has previously been co-administered with the A3AR agonist 2-383 
CL-IB-MECA confirming that the protection was directly attributed to A3ARs and not other adenosine receptor 384 
subtypes (14). 2-CL-IB-MECA dependent cerebral protection has also been described in the gerbil model of 385 
ischaemia / reperfusion injury leading to neuronal protection and decreased microglial infiltration(23). 2-CL-IB-386 
MECA has been shown to protect against simulated models of ischaemia reperfusion injury in the brain (34) and 387 
feline lung (19, 21).   388 
Our results confirm those of Maddock and colleagues showing 2-CL-IB-MECA (1nM) attenuated apoptosis and 389 
necrosis cell death in cardiac myocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation(8). 390 
Indeed, activation of A3ARs has been shown to protect rat basophilic leukaemia mast cells exposed to UV light 391 
reducing cellular apoptosis by 50% (24).  392 
MAPKs play an essential role in myocardial ischaemia reperfusion injury (35, 36). Adenosine A3 receptors have 393 
been shown to activate MAPKs ERK1/2 in Chinese hamster ovary cells exhibiting the human A3 adenosine 394 
receptor (37, 38). Our data revealed that the infarct sparing effects associated with 2-CL-IB-MECA was via 395 
recruitment of the reperfusion injury salvage kinase MEK1/2 – ERK 1/2 cell survival pathway in the isolated 396 
perfused rat heart. These results are in accordance with other studies showing that activation of A3ARs at 397 
reperfusion can limit the deleterious consequences of ischaemia reperfusion injury in a number of organs 398 
including the heart (8, 13-15, 39), lung (19, 21) and brain (23).  Our studies show that co-administration of 2-399 
CL-IB-MECA in the presence of the MEK1/2 inhibitor UO126 abolished A3 agonist dependent cardioprotection 400 
in the isolated heart. In concurrence with other cardioprotective agents, previous studies have shown 401 
cardioprotection with erythropoietin or adipocytokinevisfatin protects against ischaemic injury via activation of 402 
MEK1/2, where inhibition with UO126 an inhibitor of MEK1/2 abolished protection(40, 41). 403 
Our data showed that the administration of 2-CL-IB-MECA at reoxygenation significantly decreased the number 404 
of apoptotic and necrotic cells compared to non-treated cells. Interestingly, the MEK1/2 inhibitor when 405 
administered together with 2-CL-IB-MECA abolished 2-CL-IB-MECA-dependent anti apoptotic/necrotic 406 
effects. Our results are in accordance with numerous studies that have shown activation of A3ARs to protect 407 
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myocytes from hypoxia reoxygenation injury (32, 42). They further showed that the cytoprotection was 408 
abolished in the presence of the A3AR antagonist MRS 1191 implicating a direct role for A3ARs.Matot and 409 
colleagues have shown the A3 agonist 2-CL-IB-MECA when administered at reperfusion attenuated ischaemia 410 
reperfusion injury in the in vivo feline lung via anti apoptotic/necrotic signalling pathways (19). They further 411 
showed that the A3 antagonist MRS 1191 abolished this protective effect. A number of groups have shown 412 
activation of A3ARs to protect cells from ischaemic injury (23, 24).  This is the first study to show that activation 413 
of adenosine A3receptors at reperfusion/reoxygenation to activate the  MEK1/2-ERK1/2-BAD cell survival 414 
pathways in isolated hearts and cardiomyocytes. 415 
Our results support those of Germack and Dickenson who showed preconditioning with adenosine protected 416 
myocytes from hypoxia reoxygenation injury measured by decreased caspase 3 releases and lactate 417 
dehydrogenase release(32). They further showed this cardioprotection was associated with recruitment of 418 
MEK1/2-ERK1/2 signalling pathways where inhibition of MEK1 with PD98059 completely abolished 419 
adenosine-dependent decreases in LDH and caspase 3.  420 
Our data showed that 2-Cl-IB-MECA when administered at reperfusion significantly upregulated ERK1/2 421 
phosphorylation at the time points assessed compared to time matched controls in a UO126 sensitive manner. 422 
Our results confirm those of Dickenson and colleagues who showed recruitment of the MEK1/2 – ERK1/2 cell 423 
survival pathway in neonatal myocytes preconditioned with 2-CL-IB-MECA (32). Importantly, Matot and 424 
colleagues showed that the administration of the A3 agonist IB-MECA or the newly synthesised A3 agonist 425 
MRS3558 at the onset of reperfusion significantly protected the feline ischaemic lung from reperfusion 426 
injury(19). They further showed upregulation of ERK1/2 phosphorylation with the A3 agonists where ERK1/2 427 
phosphorylation was abolished in the presence of the A3 antagonist MRS 1191(19). 428 
Our findings showed 2-CL-IB-MECA mediated infarct sparing effects were abolished in the presence of the 429 
PI3K inhibitor Wortmannin in the isolated perfused heart. 2-CL-IB-MECA mediated protection involved 430 
recruitment of PI3K /AKT pathway, where the PI3K inhibitor Wortmannin abolished 2-CL-IB-MECA mediated 431 
protection. Similarly, Park and colleagues have shown that the protection afforded by the administration of 2-432 
CL-IB-MECA (1M) at reperfusion involves recruitment of the PI3K/AKT survival pathway as inhibition of this 433 
pathway with the PI3K inhibitor Wortmannin abolished 2-CL-IB-MECA mediated protection in the isolated 434 
perfused rat heart (43). Our findings may be explained as 2-CL-IB-MECA has been shown to activate AKT in a 435 
dose dependent manner, where 2-CL-IB-MECA increases AKT phosphorylation (31).We show for the first time 436 
that the anti-apoptotic and anti-necrotic effects of 2-CL-IB-MECA were dependent on PI3K signalling where the 437 
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cytoprotective effects were reversed in the presence of the PI3K inhibitor Wortmannin in cardiac myocytes 438 
subjected to hypoxia reoxygenation injury.  439 
Recruitment of the MEK1/2-ERK1/2 and PI3K/AKT pathways has been shown to recruit downstream effector 440 
proteins including the pro-apoptotic protein BAD(41, 44, 45). BAD remains in the cytosol when phosphorylated 441 
on either of its phosphorylation sites BADser 112 and BADser 136 bound to 14-3-3. In its phosphorylated state BADs 442 
pro-apoptotic potential is diminished and upon dephosphorylation BAD translocates to mitochondria where it 443 
leads to the release of cytochrome c from the mitochondria initiating the apoptosis(46). Our results indicate that 444 
activation of A3ARs at reperfusion upregulates BAD (Ser112) and BAD (ser136) phosphorylation thereby 445 
limiting cellular apoptosis. 446 
Caspase 3, a marker of cellular apoptosis, undergoes a conformational change from its inactive form to its active 447 
cleaved form upon receiving apoptotic signals(47). Administration of 2-CL-IB-MECA at the onset of 448 
reoxygenation reversed the increase in cleaved-caspase 3 observed in the non-treated Hyp/Reox group. These 449 
findings further support our findings that activation of A3ARs protects the myocardium from 450 
reperfusion/reoxygenation injury in the isolated rat heart/myocyte in an anti-apoptotic manner. 451 
To determine whether the decrease in cleaved-caspase 3 was dependent on the recruitment of cell survival 452 
kinases MEK1/2-ERK1/2 myocytes were incubated with 2-CL-IB-MECA in the presence and absence of the 453 
selective MEK1/2 inhibitor UO126. Our data showed that 2-Cl-IB-MECA dependent decreases in caspase 3 454 
were ameliorated by the PI3K inhibitor Wortmannin and not by the MEK1/2 inhibitor UO126. Previous studies 455 
have shown that preconditioning with adenosine (non-specific adenosine receptor agonist) or 2-CL-IB-MECA 456 
(highly specific A3AR agonist) decreased caspase 3 activity in neonatal cardiac myocytes subjected to 4 hours of 457 
hypoxia and 18 hours of reoxygenation(32). 458 
We have shown that 2-CL-IB-MECA when administered at reoxygenation protects cardiac myocytes from 459 
hypoxia/reoxygenation injury via anti-apoptotic pathways. This protective anti-apoptotic effect of 2-CL-IB-460 
MECA is supported in a number of diverse models of ischaemia/reperfusion including the lung (19-21), heart (8) 461 
and brain (23). Furthermore, 2-CL-IB-MECA has also been implicated in reducing cleaved-caspase 3 activity in 462 
the ischaemic/reperfused lung (19, 20). 463 
Numerous studies have implicated growth factors, hormones, cytokines and neurotrophic factors to protect 464 
against ischaemia reperfusion injury via recruitment of the MEK1/2-ERK1/2/BAD and PI3K/AKT/BADcell 465 
survival pathway(28). Urocortin a hormone related to the hypothalamic corticotrophin releasing factor hormone 466 
has been shown to protect the ischaemic myocardium from ischaemia reperfusion injury via upregulation of 467 
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ERK1/2 in a PD98059 (MEK1/2 inhibitor) sensitive manner as has visfatinanadipocytokine(41, 48, 49). Other 468 
studies have shown insulin and Neuregulin-1 mediated cytoprotection involved recruitment of the 469 
PI3K/AK/BAD cell survival pathway (50,51).Previous studies have shown that the cAMP Response Element-470 
Binding Protein is downstream target of the PI3K and MAPK cell survival pathway and may play in A3AR 471 
mediated cardioprotection via activation of the transcription factor CREB, which induces the expression of the 472 
antiapoptotic factor Bcl-2 (52, 53). Furthermore, studies have shown that A3AR induced cardioprotection 473 
involves ATP-sensitive potassium channels (KATP) indicating their role A3AR mediated protection (54). It is 474 
feasible that a number of pathways converge including the PI3K/AKT, MEK1-2/ERK1/2/ KATP channels 475 
mediating 2-CL-IB-MECA induced cardioprotection(17, 18).  476 
Interestingly, Ge and colleagues have shown A3AR mediated cardioprotection to be dependent on activation of 477 
A3AR on bone marrow cells via supressing inflammatory reactions in an in vivo model of ischaemia/reperfusion 478 
injury (55).The current in-vitro study shows 2-CL-IB-MECA to mediate protection for ischaemia/ reperfusion in 479 
a cell free model. Our findings may be explained as A3ARs have been shown to functionally present on 480 
cardiomyocytes where upon activation elicit protection via cell survival signalling pathways. 481 
The A1/A2 AR  agonist   5’-(N-ethylcarboxamido) adenosine (NECA) has been shown to protect the ischaemic 482 
reperfused rabbit heart from reperfusion injury when administered at reperfusion via upregulation of ERK1/2 483 
whereby inhibition of MEK1 with PD98059 blocked the protection(56). 484 
 485 
In conclusion we show for the first time that 2-CL-IB-MECA protects the ischaemic reperfused rat heart from 486 
ischaemia reperfusion injury when administered at reperfusion via recruitment of the MEK1-2/PI3K cell survival 487 
pathway. Furthermore, activation of A3ARs on the onset of reoxygenation significantly protected the hypoxic / 488 
reoxygenated adult rat cardiac myocyte from reoxygenation injury in an anti-apoptotic/necrotic manner via the 489 
MEK1/2 - PI3K cell survival pathway. Finally, 2-CL-IB-MECA reduced caspase 3 activityin a PI3K dependent 490 
and MEK1/2 independent manner. The potential pathways involved in A3AR mediated cardioprotection are 491 
summarised in Fig 11. 492 
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List of Figures 
 
Figure 1a Shows the treatment protocol used for infarct size assessment studies 
 
 
Figure 1b. Shows the treatment protocol used for tissue collection for western 
blot analysis 
 
Figure 2. The A3AR agonist 2-Cl-IB-MECA (1nM) administered at reperfusion 
significantly limits infarct size in a MEK 1/2 –ERK 1/2-dependent manner. 
*P<0.01 vs. Control. **P<0.05 vs. 2-Cl-IB-MECA. Results are shown as Mean ± 
SEM. 
 
Figure 3. The A3AR agonist 2-Cl-IB-MECA (1 nM) administered at reperfusion 
significantly limits infarct in the presence of PI3K inhibitor Wortmannin (5nM). 
#P<0.05 vs. Control, $P<0.05 vs. 2-CL-IB-MECA. Results are shown as Mean ± 
SEM. 
 
Figure 4. Assessment of the MEK 1/2 – ERK 1/2 cell survival pathway in 2-CL-
IB-MECA mediated cardioprotection in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The MEK 1/2 
inhibitor UO126 (10 M) was administered at reoxygenation in the presence and 
absence of the A3AR agonist 2-CL-IB-MECA (1 nM). Results are shown as Mean 
± SEM and are expressed as a percentage of the total cells counted. #P<0.001 vs. 
Normoxia. £P<0.001 vs. Hyp/Reox. $ <0.001 vs. 2-CL-IB-MECA. 
 
Figure 5. Assessment of the PI3K - AKT cell survival pathway in isolated adult 
rat cardiomyocytes subjected to 6 hours hypoxia and 18 hours of reoxygenation. 
The A3AR agonist 2-CL-IB-MECA (1 nM) was administered at reoxygenation in 
the presence and absence of the PI3K inhibitor Wortmannin (5 nM). Results are 
shown as Mean ± SEM and are expressed as a percentage of the total cells 
counted. # P<0.001 vs. Normoxia. £ P<0.001 vs. Hyp/Reox. $ P<0.05 vs. 2-CL-IB-
MECA. 
 
Figure 6. Assessment of p-ERK 1/2 status in isolated hearts to subjected 
ischaemia followed by 5, 10 or 20 minutes of reperfusion in the presence and 
absence of the A3 Agonist 2-CL-IB-MECA (1nM) (MECA). The MEK 1/2 
inhibitor UO126 (10 M) was administered at reperfusion in the presence and 
absence of the A3AR agonist 2-CL-IB-MECA (1 nM). Results are shown as Mean 
± SEM three individual experiments. *P<0.05 vs. Basal. **P<0.01 vs. Basal. £ 
P<0.05 vs. Control 5 min Reperfusion. # P<0.05 vs. Control 10. ### P<0.001 vs. 
MECA 10 min Reperfusion.  
 
 
Figure 7. Assessment of AKT(ser473) phosphorylation in isolated hearts to 
subjected ischaemia followed by 5, 10 or 20 minutes of reperfusion in the 
presence and absence of the A3 Agonist 2-CL-IB-MECA (1 nM) (MECA). Basal 
hearts were perfused for 60 minutes with no treatment. Results are shown as 
Mean ± SEM of three individual experiments. ** P<0.05 vs. Basal. ## P<0.01 vs. 
Control 10 10’R/F. ***P<0.001  vs.  MECA  10’R/F. ###P<0.01 vs. MECA 10min 
Reperfusion. 
 
Figure 8. Assessment of p-BAD (Ser 112) and p-BAD (ser136) activity in isolated adult 
rat cardiac myocytes subjected to 6 hours of hypoxia followed by 18 hours of 
reoxygenation. The A3 agonist 2-CL-IB-MECA (1 nM) was administered at the 
onset of reoxygenation in the presence and absence of the MEK1/2 inhibitor 
UO126 (10 M) or the PIK inhibitor Wortmannin (5nM). *P<0.05 vs. Hyp/Reox. 
# P<0.05 vs. M2-CL-IB-MECA. Mean ± SEM of 4 individual experiments. 
 
Figure 9. Cleaved-caspase 3 activity in isolated adult rat cardiac myocytes 
subjected to 6 hours of hypoxia followed by 18 hours of reoxygenation. The A3 
agonist 2-CL-IB-MECA (1 nM) was administered at the onset of reoxygenation 
in the presence and absence of the MEK1/2 inhibitor UO126(10 M). #P<0.001 
vs. Normoxia. $P<0.001 vs. Hyp/Reox. Mean ± SEM of 5 individual experiments. 
 
Figure 10. Cleaved-caspase 3 activity in isolated adult rat cardiac myocytes 
subjected to 6 hours of hypoxia followed by 18 hours of reoxygenation. The A3 
agonist 2-CL-IB-MECA (1 nM) was administered throughout reoxygenation in 
the presence and absence of the PI3 kinase inhibitor Wortmannin (5 nM). # 
P<0.001 vs. Normoxia. £ P<0.001 vs. Hyp/Reox. $ P<0.05 vs. 2-CL-IB-MECA. 
Mean ± SEM of 5 individual experiments. 
 
Figure 11. Shows a hypothetical schematic representation of the cell survival 
signalling cascades that may be involved in 2-CL-IB-MECA mediated 
cardioprotection when administered at reperfusion. 
 
 
